The UK and US have hammered out a major trade agreement that will guarantee zero duties on British medicine exports being sold in the US market.
Agreement Details of the Accord
Under the terms of the agreement, the UK has committed to raise funding on pharmaceuticals through the NHS. This pledge ensures that duties on these vital exports will stay at nothing for a period of 36 months.
This deal is in response to earlier threats to dramatically increase duties on branded pharmaceutical products, with potential rates mentioned up to 100%.
"This deal between the United Kingdom reinforces the international landscape for innovative medicines and establishes long-overdue fairness to American-British drug exports," an announcement noted.
Trade Impact
Drugs are one of the UK's most significant export categories to the America, which is by far the biggest buyer for leading British pharmaceutical firms.
Statistics indicate that in the 12 months leading up to the third quarter, the UK shipped drugs worth billions to the US. This value accounted for nearly one-fifth of total UK exports in that timeframe.
"This agreement secures work, boosts capital expenditure and sets the stage for the UK to establish itself as a international leader for life sciences," a government official remarked.
Detailed NHS Changes
The pact includes several key changes from the United Kingdom:
- Revised Affordability Limit: The UK will raise the price threshold at which it considers new therapies to be prohibitively costly by a quarter.
- Increased NHS Spending: There is a target to increase total health service expenditure on treatments from 0.3% of GDP to 0.6% over the following ten-year period.
- Refund Ceiling: The sum drug companies must refund to the NHS to prevent overspending will be capped at 15%. Previously, repayments were more than twenty percent.
Broader Context
This agreement comes amid a ongoing row between the drug companies and the UK government over medicine costs and NHS adoption.
This friction were exacerbated by arguments that US consumers were charged a premium for the same drugs than people in the Britain and the EU.
In recent months, several significant manufacturing plans in the UK have been paused or scrapped, while substantial funding commitments have been pledged toward American operations.
The Science Minister acknowledged that the NHS must increase expenditure on treatments, noting that its expenditure on drugs had declined as a proportion of its total funding over the last ten years.
